
		Home \| Profile \| Career \| Clients \| Contact \| Enquiry

Oncology(Anti-Cancer-Injectables)

Pre-Filled Syringes

Antibiotics & Anti-Infectives

New Molecules (FDC)

Liquid Ampoules / Vials

Biological Injections

Cardiovascular Injections

Neurology

Other Injectables

Hormones

Eye/ Ear/ Nasal Drops

Liquid Syrups , Dry Syrups & Redi-Mix Syrups

Sildenafil Oral Jelly

Pharmaceutical Capsules

Pharmaceutical Tablets

Tablets and Capsule

- Ardeparin Injection
- Choriogonadotrophin Alfa Injection
- Dalteparin Sodium Injection
- Erythropoietin Injection
- Vasopressin Injection
- Enoxaparin Injection
- Hydroxy Propyl Methyl Cellulose 2 Percentage W/v Injection
- Hospiral Lidocaine 1 Percentage W/v
- Lidocaine Hydrochoride 2 Percentage Injection
- Nadroparin Syrings
- Reviparin Sodium Injection
- Sodium Hyaluronate Syringe
- Tinzaparin injection

Home - Oncology(Anti-Cancer-Injectables) - Cytosine Arabinoside Injection

Cytosine Arabinoside Injection

It is phosphorylated in the body to corresponding nucleotide, which inhibits DNA repair. Cytorabine is cell cycle specific and acts primarly during S phase. Its main use is to induce remission in acute leukemia.

Composition :	100mg/1ml, 500mg/5ml, 1000mg/10ml
Indications :	Acute leukemias, lymphosarcomas.
Dosage:	3-6 mg/Kg body wt. i.v daily in 2 divided doses for 5-10 days.
Conraindications:	Hypersensitivity, Pregnancy.
Special Precautions :	Hepatic impairment. Paediatrics : Indicated in certain leukemia, under strict supervision. Pregnancy : Safety not established Lactation : Safety not established Elderly : Use with caution
Side- Effect :	Bone marrow suppression. G.I.T disturbances.
Drug Interaction :	Potentiates bone marrow depression with radiotheraphy and other myelotoxic drugs. Reduces plasma concentration of digoxin,antagonizes gentamycin. Decreased efficacy of flurocytosine.
Purity :	Not less than 99%.

» Send Enquiry

Our Products